World Wires · story 5322 · unverified · 1 source(s)

Cognition Therapeutics Schedules FDA Meeting for Zervimesine Trial

Cognition Therapeutics scheduled an October 20th Type C meeting with the FDA to align on Phase 3 trial endpoints for Zervimesine in DLB.

Open in the desk

Coverage

• Cognition Therapeutics Schedules FDA Meeting for Zervimesine Trial GlobeNewswire: public companies · tier D · clear net · 2026-09-29 11:30 UTC

What this site indexes